When did dr paul cox join neurocept and what roles has he held there?

1. What the record says about Paul Alan Cox’s organizational roles

For more than a decade Paul Alan Cox has been described in news and institutional profiles as the head, director, or executive director of Brain Chemistry Labs and the Institute for Ethnomedicine; multiple profiles list him as Executive Director or Director of Brain Chemistry Labs and of the Institute for Ethnomedicine where the neurodegenerative research is based ^{[1] [2] [3] [4]}. Event listings, speaker bios and nonprofit pages repeat that linkage: Cox “leads” Brain Chemistry Labs in Jackson Hole and serves as Director or Executive Director of the Institute for Ethnomedicine ^{[1] [5] [2]}.

2. What the sources say he has done in those roles

Reporting attributes to Cox a body of work linking ethnobotany and neurodegenerative-disease research: his teams investigated BMAA exposure hypotheses from Guam, studied longevity diets (Ogimi, Okinawa) and advanced diagnostics and clinical trials for ALS and Alzheimer’s–related work via Brain Chemistry Labs ^{[6] [7] [2] [4]}. Institutional news items describe him shepherding diagnostic development—announcing a rapid ALS blood test and aiming for broader diagnostic tools for Alzheimer’s and Parkinson’s under Brain Chemistry Labs’ umbrella ^{[3] [2]}.

3. No direct evidence tying Cox to “Neurocept” in these sources

The documents provided make no mention of a company or entity named “Neurocept” or of Paul Alan Cox joining such an organization. The sources repeatedly tie him to Brain Chemistry Labs and the Institute for Ethnomedicine; they do not mention Neurocept or any employment start date for Cox at a Neurocept ^{[1] [2] [3] [4]}. Therefore, any claim that he “joined Neurocept” is not supported by the materials you supplied—available sources do not mention Cox and Neurocept.

4. Possible reasons for confusion and how to verify further

Confusion can arise because Cox works with small labs, nonprofits and sometimes with industry partners or trial consortia; press and bios also frame him as “Director” or “Executive Director” in several contexts ^{[1] [5] [2]}. To verify a claimed association with Neurocept, one would need direct documentation—press releases from Neurocept naming Cox, corporate filings, LinkedIn employment dates, or news stories that explicitly state when he joined and in what role. Those documents are not in the current reporting ^{[1] [2] [3] [4]}.

5. Competing perspectives and limitations of the available reporting

Sources consistently describe Cox’s independent nonprofit leadership and research activities ^{[1] [2] [3] [4]}. Fortune and other profiles emphasize his nontraditional path—ethnobotanist leading small-lab drug discovery rather than a pharma executive—which makes an additional corporate appointment notable if true; yet Fortune and the institutional profiles provided do not report any Neurocept role ^{[8] [4]}. The limitation: the dataset may omit later corporate announcements or niche business press; the materials here are focused on Brain Chemistry Labs and the Institute for Ethnomedicine ^{[1] [2] [3]}.

6. Bottom line and recommended next steps for confirmation

Bottom line: available sources document Paul Alan Cox as Director/Executive Director of Brain Chemistry Labs and the Institute for Ethnomedicine and describe his scientific leadership and announcements about diagnostics and trials ^{[1] [2] [3] [4]}. They do not say he joined Neurocept or give any hiring date for that company—available sources do not mention that affiliation. If you want a definitive answer about Neurocept, request corporate press releases, a Neurocept leadership page, Cox’s own CV or LinkedIn entry, or recent SEC/registry filings; none of those documents are present in the supplied sources ^{[1] [2] [3]}.